1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Zyprexa US prosecutor: "Expect more off-label cases"

 
• By Nancy Faigen

The Acting US Attorney for Eastern District of Pennsylvania, Laurie Magid, who was very much involved in reaching the $1.4 billion settlement with Lilly regarding alleged off-label promotion of Zyprexa (olanzapine), has indicated that more of these kinds of cases should be expected. The Lilly financial settlement, announced in late January, was the largest against a single company in the history of the Department of Justice.

The Acting US Attorney for Eastern District of Pennsylvania, Laurie Magid, who was very much involved in reaching the $1.4 billion settlement with Lilly regarding alleged off-label promotion of Zyprexa (olanzapine), has indicated that more of these kinds of cases should be expected. The Lilly financial settlement, announced in late January, was the largest against a single company in the history of the Department of Justice.

Writing in the Philadelphia Inquirer, she stated: "Off-label marketing cases are not easy to bring. They can take years and involve the review of millions of documents by an alphabet...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Therapeutic Category

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.